SCHEMBL3660580

SCHEMBL3660580

CC(C)(C)c1cc(C(=O)Nc2cccc(O)c2)cc(C(C)(C)C)c1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
MAPT P10636 2/20 0.57
LMNA P02545 1/20 0.57
MAPK1 P28482 2/20 0.56
TP53 P04637 1/20 0.56
ALDH1A1 P00352 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HTT P42858 1/20 0.55
TOP1 P11387 1/20 0.54
TOP2A P11388 1/20 0.54
TOP2B Q02880 1/20 0.54
CYP1A2 P05177 1/20 0.53
KCNK9 Q9NPC2 2/20 0.51
PKM P14618 1/20 0.49
NLRP3 Q96P20 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC8 Q9BY41 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4652364 0.95 MEN1 (0.56) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL7129217 0.86 PTGS1 (0.57) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL9417262 0.86 MEN1 (0.62) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL3655211 0.83 NQO2 (0.62) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL9417400 0.82 NR1H4 (0.58) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL7292693 0.82 KCNK9 (0.75) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3863282 0.79 KMT2A (0.77) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL6544007 0.79 GAA (0.50) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL11807786 0.79 RAB9A (0.59) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL4319185 0.78 SNCA (0.65) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9364424-B2 Topical cosmetic skin lightening compositions and methods of use thereof STIEFEL LABORATORIES, INC. (US) 2016-06-14 US disclosed
US-20160074315-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. 2016-03-17 US disclosed
EP-2219600-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2010-08-25 EP disclosed
WO-2009067095-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2009-05-28 WO disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC MEN1 2813/4885KMT2A 998/4885NPC1 4845/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR MEN1 1028/4885KMT2A 847/4885NPC1 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.